1. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup
by Jacques Delaunay, Norbert Vey, Thierry Leblanc, Pierre Fenaux, Françoise Rigal-Huguet, Francis Witz, Thierry Lamy, Anne Auvrignon, Didier Blaise, Arnaud Pigneux, Francine Mugneret, Christian Bastard, Nicole Dastugue, Jacqueline Van den Akker, Denis Fière, Josy Reiffers, Sylvie Castaigne, Guy Leverger, Jean-Luc Harousseau, and Hervé Dombret
Blood
Volume 102(2):
July 15, 2003
©2003 by American Society of Hematology

2. Prognostic impact of age on outcome of CR patients.
Prognostic impact of age on outcome of CR patients. (A) DFS. (B) Cumulative incidence of relapse.
Jacques Delaunay et al. Blood 2003;102:
©2003 by American Society of Hematology

3. Prognostic impact of allogeneic HSCT versus chemotherapy on outcome of CR patients up to 50 years of age (intent-to-treat analysis).
Prognostic impact of allogeneic HSCT versus chemotherapy on outcome of CR patients up to 50 years of age (intent-to-treat analysis). (A) DFS. (B) Overall survival of CR patients.
Jacques Delaunay et al. Blood 2003;102:
©2003 by American Society of Hematology

4. Prognostic impact of the postremission chemotherapy (IDAC versus HDAC) on outcome of CR patients (intent-to-treat analysis).
Prognostic impact of the postremission chemotherapy (IDAC versus HDAC) on outcome of CR patients (intent-to-treat analysis). (A) DFS. (B) Cumulative incidence of death in CR.
Jacques Delaunay et al. Blood 2003;102:
©2003 by American Society of Hematology

5. Comparative evaluation of age and WBC prognostic significance in t(8;21) and inv(16)/t(16;16) AML. (A) Adjusted P values for DFS according to selected age cutpoints.
Comparative evaluation of age and WBC prognostic significance in t(8;21) and inv(16)/t(16;16) AML. (A) Adjusted P values for DFS according to selected age cutpoints. (B) Adjusted P values for DFS according to selected WBC cutpoints. P values for DFS comparison, after adjustment based on an approximation to the improved Bonferroni inequality,16 are given according to selected age (A) and WBC (B) cutpoints in each CBF-AML subtype. In inv(16)/t(16;16) AML, the optimal age cutpoint was 35 years (adjusted P value = .001). In t(8;21) AML, the optimal WBC cutpoint was 30 × 109/L (adjusted P value = .014).
Jacques Delaunay et al. Blood 2003;102:
©2003 by American Society of Hematology